Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 218

1.

Can we predict cognitive decline after initial diagnosis of multiple sclerosis? Results from the German National early MS cohort (KKNMS).

Johnen A, Bürkner PC, Landmeyer NC, Ambrosius B, Calabrese P, Motte J, Hessler N, Antony G, König IR, Klotz L, Hoshi MM, Aly L, Groppa S, Luessi F, Paul F, Tackenberg B, Bergh FT, Kümpfel T, Tumani H, Stangel M, Weber F, Bayas A, Wildemann B, Heesen C, Zettl UK, Zipp F, Hemmer B, Meuth SG, Gold R, Wiendl H, Salmen A; German Competence Network Multiple Sclerosis (KKNMS).

J Neurol. 2018 Dec 4. doi: 10.1007/s00415-018-9142-y. [Epub ahead of print]

PMID:
30515631
2.

Disease Modification in Multiple Sclerosis by Flupirtine-Results of a Randomized Placebo Controlled Phase II Trial.

Dörr J, Wernecke KD, Würfel J, Bellmann-Strobl J, Siffrin V, Sättler MB, Simons M, Linsa A, Tumani H, Paul F.

Front Neurol. 2018 Oct 9;9:842. doi: 10.3389/fneur.2018.00842. eCollection 2018.

3.

Apheresis therapies for NMOSD attacks: A retrospective study of 207 therapeutic interventions.

Kleiter I, Gahlen A, Borisow N, Fischer K, Wernecke KD, Hellwig K, Pache F, Ruprecht K, Havla J, Kümpfel T, Aktas O, Hartung HP, Ringelstein M, Geis C, Kleinschnitz C, Berthele A, Hemmer B, Angstwurm K, Stellmann JP, Schuster S, Stangel M, Lauda F, Tumani H, Mayer C, Krumbholz M, Zeltner L, Ziemann U, Linker R, Schwab M, Marziniak M, Then Bergh F, Hofstadt-van Oy U, Neuhaus O, Zettl UK, Faiss J, Wildemann B, Paul F, Jarius S, Trebst C; NEMOS (Neuromyelitis Optica Study Group).

Neurol Neuroimmunol Neuroinflamm. 2018 Sep 26;5(6):e504. doi: 10.1212/NXI.0000000000000504. eCollection 2018 Nov.

4.

Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis.

Verde F, Steinacker P, Weishaupt JH, Kassubek J, Oeckl P, Halbgebauer S, Tumani H, von Arnim CAF, Dorst J, Feneberg E, Mayer B, Müller HP, Gorges M, Rosenbohm A, Volk AE, Silani V, Ludolph AC, Otto M.

J Neurol Neurosurg Psychiatry. 2018 Oct 11. pii: jnnp-2018-318704. doi: 10.1136/jnnp-2018-318704. [Epub ahead of print]

PMID:
30309882
5.

Short-term and long-term effects of immunoadsorption in refractory chronic inflammatory demyelinating polyneuropathy: a prospective study in 17 patients.

Dorst J, Ludolph AC, Senel M, Tumani H.

J Neurol. 2018 Dec;265(12):2906-2915. doi: 10.1007/s00415-018-9082-6. Epub 2018 Oct 6.

PMID:
30293110
6.

Serum GFAP as a biomarker for disease severity in multiple sclerosis.

Abdelhak A, Huss A, Kassubek J, Tumani H, Otto M.

Sci Rep. 2018 Oct 4;8(1):14798. doi: 10.1038/s41598-018-33158-8.

7.

Comprehensive microRNA expression profiling in cerebrospinal fluid distinguishes between neurological disease classes.

Grasedieck S, Mulaw M, Sperb N, Wessinger K, Rouhi A, Bommer M, Bromberg JEC, Otto M, Tumani H, von Arnim CAF, Mertens D, Kuchenbauer F.

Neuropathol Appl Neurobiol. 2018 Apr 21. doi: 10.1111/nan.12491. [Epub ahead of print] No abstract available.

PMID:
29679382
8.

Intrathecal immunoglobulin M production: A promising high-risk marker in clinically isolated syndrome patients.

Huss A, Abdelhak A, Halbgebauer S, Mayer B, Senel M, Otto M, Tumani H.

Ann Neurol. 2018 May;83(5):1032-1036. doi: 10.1002/ana.25237. Epub 2018 May 11.

PMID:
29665046
9.

MOG-IgG in primary and secondary chronic progressive multiple sclerosis: a multicenter study of 200 patients and review of the literature.

Jarius S, Ruprecht K, Stellmann JP, Huss A, Ayzenberg I, Willing A, Trebst C, Pawlitzki M, Abdelhak A, Grüter T, Leypoldt F, Haas J, Kleiter I, Tumani H, Fechner K, Reindl M, Paul F, Wildemann B.

J Neuroinflammation. 2018 Mar 19;15(1):88. doi: 10.1186/s12974-018-1108-6.

10.

White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation.

Teunissen CE, Otto M, Engelborghs S, Herukka SK, Lehmann S, Lewczuk P, Lleó A, Perret-Liaudet A, Tumani H, Turner MR, Verbeek MM, Wiltfang J, Zetterberg H, Parnetti L, Blennow K.

Alzheimers Res Ther. 2018 Mar 15;10(1):30. doi: 10.1186/s13195-018-0359-x. Review.

11.

Treatment choices and neuropsychological symptoms of a large cohort of early MS.

von Bismarck O, Dankowski T, Ambrosius B, Hessler N, Antony G, Ziegler A, Hoshi MM, Aly L, Luessi F, Groppa S, Klotz L, Meuth SG, Tackenberg B, Stoppe M, Then Bergh F, Tumani H, Kümpfel T, Stangel M, Heesen C, Wildemann B, Paul F, Bayas A, Warnke C, Weber F, Linker RA, Ziemann U, Zettl UK, Zipp F, Wiendl H, Hemmer B, Gold R, Salmen A.

Neurol Neuroimmunol Neuroinflamm. 2018 Mar 1;5(3):e446. doi: 10.1212/NXI.0000000000000446. eCollection 2018 May.

12.

Development and Validation of an Ultrasensitive Procalcitonin Sandwich Immunoassay.

Carcamo Yañez VA, Göpfert JC, Otto M, Tumani H, Peter A, Joos TO.

High Throughput. 2017 Nov 16;6(4). pii: E18. doi: 10.3390/ht6040018.

13.

Chitotriosidase (CHIT1) is increased in microglia and macrophages in spinal cord of amyotrophic lateral sclerosis and cerebrospinal fluid levels correlate with disease severity and progression.

Steinacker P, Verde F, Fang L, Feneberg E, Oeckl P, Roeber S, Anderl-Straub S, Danek A, Diehl-Schmid J, Fassbender K, Fliessbach K, Foerstl H, Giese A, Jahn H, Kassubek J, Kornhuber J, Landwehrmeyer GB, Lauer M, Pinkhardt EH, Prudlo J, Rosenbohm A, Schneider A, Schroeter ML, Tumani H, von Arnim CAF, Weishaupt J, Weydt P, Ludolph AC, Yilmazer Hanke D, Otto M; FTLDc study group.

J Neurol Neurosurg Psychiatry. 2018 Mar;89(3):239-247. doi: 10.1136/jnnp-2017-317138. Epub 2017 Nov 15.

PMID:
29142138
14.

Preface.

Deisenhammer F, Teunissen CE, Tumani H.

Handb Clin Neurol. 2017;146:ix. doi: 10.1016/B978-0-12-804279-3.09987-1. No abstract available.

PMID:
29110783
15.

Epilepsy.

Fauser S, Tumani H.

Handb Clin Neurol. 2017;146:259-266. doi: 10.1016/B978-0-12-804279-3.00015-0. Review.

PMID:
29110774
16.

The cerebrospinal fluid and barriers - anatomic and physiologic considerations.

Tumani H, Huss A, Bachhuber F.

Handb Clin Neurol. 2017;146:21-32. doi: 10.1016/B978-0-12-804279-3.00002-2. Review.

PMID:
29110772
17.

Safety and in vivo immune assessment of escalating doses of oral laquinimod in patients with RRMS.

Ziemssen T, Tumani H, Sehr T, Thomas K, Paul F, Richter N, Samara E, Spiegelstein O, Sorani E, Bar-Ilan O, Mimrod D, Hayardeny L.

J Neuroinflammation. 2017 Aug 31;14(1):172. doi: 10.1186/s12974-017-0945-z.

18.

GFAP in early multiple sclerosis: A biomarker for inflammation.

Kassubek R, Gorges M, Schocke M, Hagenston VAM, Huss A, Ludolph AC, Kassubek J, Tumani H.

Neurosci Lett. 2017 Sep 14;657:166-170. doi: 10.1016/j.neulet.2017.07.050. Epub 2017 Aug 9.

PMID:
28802830
19.

CSF profile in primary progressive multiple sclerosis: Re-exploring the basics.

Abdelhak A, Hottenrott T, Mayer C, Hintereder G, Zettl UK, Stich O, Tumani H.

PLoS One. 2017 Aug 10;12(8):e0182647. doi: 10.1371/journal.pone.0182647. eCollection 2017.

20.

Intrathecal immunoglobulin synthesis in patients with symptomatic epilepsy and epilepsy of unknown etiology ('cryptogenic').

Fauser S, Soellner C, Bien CG, Tumani H.

Eur J Neurol. 2017 Sep;24(9):1188-1190. doi: 10.1111/ene.13348. Epub 2017 Jul 5.

PMID:
28677890
21.

Primary Progressive Multiple Sclerosis: Putting Together the Puzzle.

Abdelhak A, Weber MS, Tumani H.

Front Neurol. 2017 May 31;8:234. doi: 10.3389/fneur.2017.00234. eCollection 2017. Review.

22.

Consensus guidelines for lumbar puncture in patients with neurological diseases.

Engelborghs S, Niemantsverdriet E, Struyfs H, Blennow K, Brouns R, Comabella M, Dujmovic I, van der Flier W, Frölich L, Galimberti D, Gnanapavan S, Hemmer B, Hoff E, Hort J, Iacobaeus E, Ingelsson M, Jan de Jong F, Jonsson M, Khalil M, Kuhle J, Lleó A, de Mendonça A, Molinuevo JL, Nagels G, Paquet C, Parnetti L, Roks G, Rosa-Neto P, Scheltens P, Skårsgard C, Stomrud E, Tumani H, Visser PJ, Wallin A, Winblad B, Zetterberg H, Duits F, Teunissen CE.

Alzheimers Dement (Amst). 2017 May 18;8:111-126. doi: 10.1016/j.dadm.2017.04.007. eCollection 2017.

23.

Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response.

Stellmann JP, Krumbholz M, Friede T, Gahlen A, Borisow N, Fischer K, Hellwig K, Pache F, Ruprecht K, Havla J, Kümpfel T, Aktas O, Hartung HP, Ringelstein M, Geis C, Kleinschnitz C, Berthele A, Hemmer B, Angstwurm K, Young KL, Schuster S, Stangel M, Lauda F, Tumani H, Mayer C, Zeltner L, Ziemann U, Linker RA, Schwab M, Marziniak M, Then Bergh F, Hofstadt-van Oy U, Neuhaus O, Zettl U, Faiss J, Wildemann B, Paul F, Jarius S, Trebst C, Kleiter I; NEMOS (Neuromyelitis Optica Study Group).

J Neurol Neurosurg Psychiatry. 2017 Aug;88(8):639-647. doi: 10.1136/jnnp-2017-315603. Epub 2017 Jun 1.

24.

Reduced cGMP levels in CSF of AD patients correlate with severity of dementia and current depression.

Hesse R, Lausser L, Gummert P, Schmid F, Wahler A, Schnack C, Kroker KS, Otto M, Tumani H, Kestler HA, Rosenbrock H, von Arnim CA.

Alzheimers Res Ther. 2017 Mar 9;9(1):17. doi: 10.1186/s13195-017-0245-y.

25.

Gain-of-function STAT1 mutations are associated with intracranial aneurysms.

Dadak M, Jacobs R, Skuljec J, Jirmo AC, Yildiz Ö, Donnerstag F, Baerlecken NT, Schmidt RE, Lanfermann H, Skripuletz T, Schwenkenbecher P, Kleinschnitz C, Tumani H, Stangel M, Pul R.

Clin Immunol. 2017 May;178:79-85. doi: 10.1016/j.clim.2017.01.012. Epub 2017 Feb 2.

PMID:
28161409
26.

Oxidative stress in drug-naïve first episode patients with schizophrenia and major depression: effects of disease acuity and potential confounders.

Jordan W, Dobrowolny H, Bahn S, Bernstein HG, Brigadski T, Frodl T, Isermann B, Lessmann V, Pilz J, Rodenbeck A, Schiltz K, Schwedhelm E, Tumani H, Wiltfang J, Guest PC, Steiner J.

Eur Arch Psychiatry Clin Neurosci. 2018 Mar;268(2):129-143. doi: 10.1007/s00406-016-0749-7. Epub 2016 Dec 2.

PMID:
27913877
27.

[Importance of cerebrospinal fluid diagnostics in neuropsychiatric diseases].

Tumani H, Uhr M, Wildemann B, Wick M.

Nervenarzt. 2016 Dec;87(12):1259-1260. German. No abstract available.

PMID:
27853851
28.

Validation of a multiplexing technique to determine the intrathecal, polyspecific antiviral immune response in multiple sclerosis.

Huss A, Buttmann M, Brecht I, Weishaupt A, Otto M, Tumani H.

Expert Rev Mol Diagn. 2016 Dec;16(12):1353-1356. Epub 2016 Oct 31.

PMID:
27759441
29.

[Strategies for cerebrospinal fluid analysis - Integrated results report].

Uhr M, Tumani H, Lange P.

Nervenarzt. 2016 Dec;87(12):1271-1275. Review. German.

PMID:
27785524
30.

Influence of female sex and fertile age on neuromyelitis optica spectrum disorders.

Borisow N, Kleiter I, Gahlen A, Fischer K, Wernecke KD, Pache F, Ruprecht K, Havla J, Krumbholz M, Kümpfel T, Aktas O, Ringelstein M, Geis C, Kleinschnitz C, Berthele A, Hemmer B, Angstwurm K, Weissert R, Stellmann JP, Schuster S, Stangel M, Lauda F, Tumani H, Mayer C, Zeltner L, Ziemann U, Linker RA, Schwab M, Marziniak M, Then Bergh F, Hofstadt-van Oy U, Neuhaus O, Winkelmann A, Marouf W, Rückriem L, Faiss J, Wildemann B, Paul F, Jarius S, Trebst C, Hellwig K; NEMOS (Neuromyelitis Optica Study Group).

Mult Scler. 2017 Jul;23(8):1092-1103. doi: 10.1177/1352458516671203. Epub 2016 Oct 6.

PMID:
27758954
31.

Importance of cerebrospinal fluid analysis in the era of McDonald 2010 criteria: a German-Austrian retrospective multicenter study in patients with a clinically isolated syndrome.

Huss AM, Halbgebauer S, Öckl P, Trebst C, Spreer A, Borisow N, Harrer A, Brecht I, Balint B, Stich O, Schlegel S, Retzlaff N, Winkelmann A, Roesler R, Lauda F, Yildiz Ö, Voß E, Muche R, Rauer S, Bergh FT, Otto M, Paul F, Wildemann B, Kraus J, Ruprecht K, Stangel M, Buttmann M, Zettl UK, Tumani H.

J Neurol. 2016 Dec;263(12):2499-2504. Epub 2016 Oct 11.

32.

Treatment-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: A Comprehensive Review of Current Evidence and Future Needs.

D'Amico E, Zanghì A, Leone C, Tumani H, Patti F.

Drug Saf. 2016 Dec;39(12):1163-1174. Review.

PMID:
27696299
33.

Decreased IL-8 levels in CSF and serum of AD patients and negative correlation of MMSE and IL-1β.

Hesse R, Wahler A, Gummert P, Kirschmer S, Otto M, Tumani H, Lewerenz J, Schnack C, von Arnim CA.

BMC Neurol. 2016 Sep 26;16(1):185.

34.

[Cerebrospinal fluid diagnostics in multiple sclerosis].

Ruprecht K, Tumani H.

Nervenarzt. 2016 Dec;87(12):1282-1287. Review. German.

PMID:
27649986
35.

Novel multiple sclerosis susceptibility loci implicated in epigenetic regulation.

Andlauer TF, Buck D, Antony G, Bayas A, Bechmann L, Berthele A, Chan A, Gasperi C, Gold R, Graetz C, Haas J, Hecker M, Infante-Duarte C, Knop M, Kümpfel T, Limmroth V, Linker RA, Loleit V, Luessi F, Meuth SG, Mühlau M, Nischwitz S, Paul F, Pütz M, Ruck T, Salmen A, Stangel M, Stellmann JP, Stürner KH, Tackenberg B, Then Bergh F, Tumani H, Warnke C, Weber F, Wiendl H, Wildemann B, Zettl UK, Ziemann U, Zipp F, Arloth J, Weber P, Radivojkov-Blagojevic M, Scheinhardt MO, Dankowski T, Bettecken T, Lichtner P, Czamara D, Carrillo-Roa T, Binder EB, Berger K, Bertram L, Franke A, Gieger C, Herms S, Homuth G, Ising M, Jöckel KH, Kacprowski T, Kloiber S, Laudes M, Lieb W, Lill CM, Lucae S, Meitinger T, Moebus S, Müller-Nurasyid M, Nöthen MM, Petersmann A, Rawal R, Schminke U, Strauch K, Völzke H, Waldenberger M, Wellmann J, Porcu E, Mulas A, Pitzalis M, Sidore C, Zara I, Cucca F, Zoledziewska M, Ziegler A, Hemmer B, Müller-Myhsok B.

Sci Adv. 2016 Jun 17;2(6):e1501678. doi: 10.1126/sciadv.1501678. eCollection 2016 Jun.

36.

Distinct oligoclonal band antibodies in multiple sclerosis recognize ubiquitous self-proteins.

Brändle SM, Obermeier B, Senel M, Bruder J, Mentele R, Khademi M, Olsson T, Tumani H, Kristoferitsch W, Lottspeich F, Wekerle H, Hohlfeld R, Dornmair K.

Proc Natl Acad Sci U S A. 2016 Jul 12;113(28):7864-9. doi: 10.1073/pnas.1522730113. Epub 2016 Jun 20.

37.

Cognitive Reserve in Alzheimer's Dementia: Diagnostic Accuracy of a Testing-the-Limits Paradigm.

Küster OC, Kösel J, Spohn S, Schurig N, Tumani H, von Arnim CA, Uttner I.

J Alzheimers Dis. 2016 Mar 29;52(2):519-28. doi: 10.3233/JAD-151141.

PMID:
27031485
38.

Detection of intrathecal immunoglobulin G synthesis by capillary isoelectric focusing immunoassay in oligoclonal band negative multiple sclerosis.

Halbgebauer S, Huss A, Buttmann M, Steinacker P, Oeckl P, Brecht I, Weishaupt A, Tumani H, Otto M.

J Neurol. 2016 May;263(5):954-960. doi: 10.1007/s00415-016-8094-3. Epub 2016 Mar 19.

PMID:
26995358
39.

[Monitoring of blood parameters under course-modified MS therapy : Substance-specific relevance and current recommendations for action].

Klotz L, Berthele A, Brück W, Chan A, Flachenecker P, Gold R, Haghikia A, Hellwig K, Hemmer B, Hohlfeld R, Korn T, Kümpfel T, Lang M, Limmroth V, Linker RA, Meier U, Meuth SG, Paul F, Salmen A, Stangel M, Tackenberg B, Tumani H, Warnke C, Weber MS, Ziemssen T, Zipp F, Wiendl H.

Nervenarzt. 2016 Jun;87(6):645-59. doi: 10.1007/s00115-016-0077-1. Review. German.

PMID:
26927677
40.

6-sulpho LacNAc(+) dendritic cells accumulate in various inflammatory, but not ischaemic conditions of the central nervous system.

Thomas K, Metz I, Tumani H, Brück W, Ziemssen T.

Neuropathol Appl Neurobiol. 2016 Jun;42(4):394-8. doi: 10.1111/nan.12313. No abstract available.

PMID:
26844946
41.

Progranulin as a candidate biomarker for therapeutic trial in patients with ALS and FTLD.

Feneberg E, Steinacker P, Volk AE, Weishaupt JH, Wollmer MA, Boxer A, Tumani H, Ludolph AC, Otto M.

J Neural Transm (Vienna). 2016 Mar;123(3):289-96. doi: 10.1007/s00702-015-1486-1. Epub 2015 Dec 11.

PMID:
26659729
42.

Retinal involvement in amyotrophic lateral sclerosis: a study with optical coherence tomography and diffusion tensor imaging.

Hübers A, Müller HP, Dreyhaupt J, Böhm K, Lauda F, Tumani H, Kassubek J, Ludolph AC, Pinkhardt EH.

J Neural Transm (Vienna). 2016 Mar;123(3):281-7. doi: 10.1007/s00702-015-1483-4. Epub 2015 Nov 18.

PMID:
26582428
43.

Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses.

Kleiter I, Gahlen A, Borisow N, Fischer K, Wernecke KD, Wegner B, Hellwig K, Pache F, Ruprecht K, Havla J, Krumbholz M, Kümpfel T, Aktas O, Hartung HP, Ringelstein M, Geis C, Kleinschnitz C, Berthele A, Hemmer B, Angstwurm K, Stellmann JP, Schuster S, Stangel M, Lauda F, Tumani H, Mayer C, Zeltner L, Ziemann U, Linker R, Schwab M, Marziniak M, Then Bergh F, Hofstadt-van Oy U, Neuhaus O, Winkelmann A, Marouf W, Faiss J, Wildemann B, Paul F, Jarius S, Trebst C; Neuromyelitis Optica Study Group.

Ann Neurol. 2016 Feb;79(2):206-16. doi: 10.1002/ana.24554. Epub 2015 Nov 26.

PMID:
26537743
44.

Successful Replication of GWAS Hits for Multiple Sclerosis in 10,000 Germans Using the Exome Array.

Dankowski T, Buck D, Andlauer TF, Antony G, Bayas A, Bechmann L, Berthele A, Bettecken T, Chan A, Franke A, Gold R, Graetz C, Haas J, Hecker M, Herms S, Infante-Duarte C, Jöckel KH, Kieseier BC, Knier B, Knop M, Kümpfel T, Lichtner P, Lieb W, Lill CM, Limmroth V, Linker RA, Loleit V, Meuth SG, Moebus S, Müller-Myhsok B, Nischwitz S, Nöthen MM, Paul F, Pütz M, Ruck T, Salmen A, Stangel M, Stellmann JP, Strauch K, Stürner KH, Tackenberg B, Then Bergh F, Tumani H, Waldenberger M, Weber F, Wiendl H, Wildemann B, Zettl UK, Ziemann U, Zipp F, Hemmer B, Ziegler A; German Competence Network for Multiple Sclerosis (KKNMS).

Genet Epidemiol. 2015 Dec;39(8):601-8. doi: 10.1002/gepi.21933. Epub 2015 Oct 26.

PMID:
26497834
45.

Deregulation of microRNA-181c in cerebrospinal fluid of patients with clinically isolated syndrome is associated with early conversion to relapsing-remitting multiple sclerosis.

Ahlbrecht J, Martino F, Pul R, Skripuletz T, Sühs KW, Schauerte C, Yildiz Ö, Trebst C, Tasto L, Thum S, Pfanne A, Roesler R, Lauda F, Hecker M, Zettl UK, Tumani H, Thum T, Stangel M.

Mult Scler. 2016 Aug;22(9):1202-14. doi: 10.1177/1352458515613641. Epub 2015 Oct 22.

PMID:
26493127
46.

Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients.

Steinacker P, Feneberg E, Weishaupt J, Brettschneider J, Tumani H, Andersen PM, von Arnim CA, Böhm S, Kassubek J, Kubisch C, Lulé D, Müller HP, Muche R, Pinkhardt E, Oeckl P, Rosenbohm A, Anderl-Straub S, Volk AE, Weydt P, Ludolph AC, Otto M.

J Neurol Neurosurg Psychiatry. 2016 Jan;87(1):12-20. doi: 10.1136/jnnp-2015-311387. Epub 2015 Aug 21.

PMID:
26296871
47.

[Current aspects of therapy conversion for multiple sclerosis].

Kolber P, Luessi F, Meuth SG, Klotz L, Korn T, Trebst C, Tackenberg B, Kieseier B, Kümpfel T, Fleischer V, Tumani H, Wildemann B, Lang M, Flachenecker P, Meier U, Brück W, Limmroth V, Haghikia A, Hartung HP, Stangel M, Hohlfeld R, Hemmer B, Gold R, Wiendl H, Zipp F.

Nervenarzt. 2015 Oct;86(10):1236-47. doi: 10.1007/s00115-015-4368-8. Review. German.

PMID:
26269289
48.

Brain-Specific Cytoskeletal Damage Markers in Cerebrospinal Fluid: Is There a Common Pattern between Amyotrophic Lateral Sclerosis and Primary Progressive Multiple Sclerosis?

Abdelhak A, Junker A, Brettschneider J, Kassubek J, Ludolph AC, Otto M, Tumani H.

Int J Mol Sci. 2015 Jul 31;16(8):17565-88. doi: 10.3390/ijms160817565. Review.

49.

Validation of kappa free light chains as a diagnostic biomarker in multiple sclerosis and clinically isolated syndrome: A multicenter study.

Presslauer S, Milosavljevic D, Huebl W, Aboulenein-Djamshidian F, Krugluger W, Deisenhammer F, Senel M, Tumani H, Hegen H.

Mult Scler. 2016 Apr;22(4):502-10. doi: 10.1177/1352458515594044. Epub 2015 Jul 21.

PMID:
26199348
50.

Listeria Meningitis Complicating Alemtuzumab Treatment in Multiple Sclerosis--Report of Two Cases.

Rau D, Lang M, Harth A, Naumann M, Weber F, Tumani H, Bayas A.

Int J Mol Sci. 2015 Jun 29;16(7):14669-76. doi: 10.3390/ijms160714669.

Supplemental Content

Loading ...
Support Center